Integrating Therapeutic Drug Monitoring and Metabolomics to Explore Interindividual Variability in Lamotrigine Response in Epilepsy
Drug Design, Development and Therapy · 2026-05 · Volume 20 · 1-12
DOI: 10.2147/dddt.s593268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-05. Verfasst von Xiuwei Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China. Hauptthemen laut MEDLINE: Lamotrigine, Epilepsy, Metabolomics, Drug Monitoring. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
Lamotrigine (LTG) is a first-line antiseizure medication, yet substantial interindividual variability in therapeutic response remains a major clinical challenge. This study integrated therapeutic drug monitoring (TDM) and metabolomics to explore pharmacokinetic and metabolic factors associated with LTG efficacy in patients with epilepsy.
Methods
A total of 141 epilepsy patients receiving LTG therapy were retrospectively enrolled and classified as responders or non‑responders by 6-month seizure frequency reduction. LTG plasma concentrations were measured using HPLC–DAD. Untargeted UPLC–MS/MS metabolomics and multivariate analysis were performed on serum from 10 responders and 10 non-responders with LTG > 5.15 mg/L, with differential amino acids quantified. Differential metabolites were further quantified, with a focus on amino acids.
Results
Mean LTG plasma concentration was significantly higher in responders (7.55 ± 4.57 mg/L) than non‑responders (4.53 ± 2.94 mg/L; P = 0.001). Receiver operating characteristic (ROC) curve analysis suggested 5.15 mg/L as the optimal cut‑off for discriminating responders from non‑responders, within the conventional ILAE reference range (2.5– 15 mg/L). Concomitant use of valproic acid (VPA) increased LTG exposure, was more prevalent among responders, and enabled seizure control at lower LTG doses. Metabolomic analysis in the high‑concentration subgroup revealed a distinct amino acid profile in responders, characterized by higher proline and lower lysine and cystine (P < 0.05). These changes suggest reduced oxidative stress and improved neuronal stability in responders.
Conclusion
Higher LTG plasma concentrations were associated with better seizure control, and VPA co‑administration enhances LTG exposure and efficacy. The distinct amino acid profile in high-concentration responders suggests amino acid metabolism and redox balance may modulate LTG efficacy. Infographic on epilepsy treatment: cohort, TDM and metabolomics for therapy optimization.On the left, it mentions a cohort of 141 patients with epilepsy receiving LTG, divided into responders (greater than or equal to 50 percent seizure reduction in 6 months) and non-responders. The middle section, labeled TDM, displays a bar graph with a cut-off at 5.15 milligrams per liter, indicating responders with 7.55 milligrams per liter and non-responders with 4.53 milligrams per liter. It notes that valproic acid co-medication increases LTG exposure. The right section, labeled Metabolomics, shows a diagram with proline increasing, lysine and cystine decreasing, indicating a distinct metabolic signature associated with a favorable response. A note at the bottom states that higher LTT concentration leads to better seizure control and TDM plus metabolomics support individualized therapy optimization. Keywords: lamotrigine, epilepsy, therapeutic drug monitoring, metabolomics, amino acid
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
- Clinical Research Center, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Zitieren
APA
Shen, X., Jin, R., Xu, N., Miao, Y., Zheng, Z., Wang, J., You, M., Lin, F., & Hu, L. (2026). Integrating Therapeutic Drug Monitoring and Metabolomics to Explore Interindividual Variability in Lamotrigine Response in Epilepsy. Drug Design, Development and Therapy, Volume 20, 1-12. https://doi.org/10.2147/dddt.s593268
Vancouver
Shen X, Jin R, Xu N, Miao Y, Zheng Z, Wang J, et al. Integrating Therapeutic Drug Monitoring and Metabolomics to Explore Interindividual Variability in Lamotrigine Response in Epilepsy. Drug Design, Development and Therapy. 2026;Volume 20:1-12. doi:10.2147/dddt.s593268
BibTeX
@article{Shen2026,
author = {Shen, Xiuwei and Jin, Ruyi and Xu, Ningxia and Miao, Yuqing and Zheng, Zhenfei and Wang, Jianxing and You, Minjie and Lin, Feiyan and Hu, Lufeng},
title = {Integrating Therapeutic Drug Monitoring and Metabolomics to Explore Interindividual Variability in Lamotrigine Response in Epilepsy},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--12},
doi = {10.2147/dddt.s593268}
}
EUVIMED